Related Experiment Videos
Dislodgment and accelerated degradation of Ras
1Department of Neurobiochemistry, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel.
Abstract:
Membrane anchorage of Ras oncoproteins, required for transforming activity, depends on their carboxy-terminal farnesylcysteine. We previously showed that S-trans,trans-farnesylthiosalicylic acid (FTS), a synthetic farnesylcysteine mimetic, inhibits growth of ErbB2- and Ras-transformed cells, but not of v-Raf-transformed cells, suggesting that FTS interferes specifically with Ras functions. Here we demonstrate that FTS dislodges Ras from membranes of H-Ras-transformed (EJ) cells, facilitating its degradation and decreasing total cellular Ras. The dislodged Ras that was transiently present in the cytosol was degraded relatively rapidly, causing a decrease of up to 80% in total cellular Ras. The half-life of Ras was 10 +/- 4 h in FTS-treated EJ cells and 27 +/- 4 h in controls. The dislodgment of membrane Ras and decrease in total cellular Ras were dose-dependent: 50% of the effects occurred at 10-15 microM, comparable to concentrations (7-10 microM) required for 50% growth inhibition in EJ cells. Higher concentrations of FTS (25-50 microM) were required to dislodge Ras from Rat-1 cell membranes expressing normal Ras, suggesting some selectivity of FTS toward oncogenic Ras. Membrane localization of the prenylated G beta gamma of heterotrimeric G proteins was not affected by FTS in EJ cells. An FTS-related compound, N-acetyl-S-farnesyl-L-cysteine, which does not inhibit EJ cell growth, did not affect Ras. FTS did not inhibit growth of Rat-1 cells transformed by N-myristylated H-Ras and did not reduce the total amount of this Ras isoform. The results suggest that FTS affects docking of Ras in the cell membrane in a rather specific manner, rendering the protein susceptible to proteolytic degradation.
Insights
S-trans,trans-farnesylthiosalicylic acid (FTS) dislodges oncogenic Ras proteins from cell membranes, leading to their degradation and reduced cellular levels. This specific action inhibits cancer cell growth, offering a targeted therapeutic approach.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Ras oncoproteins are crucial for cancer cell transformation.
- Membrane anchorage of Ras is essential for its activity.
- Farnesylcysteine is a key component for Ras membrane binding.
Purpose of the Study:
- To investigate the mechanism of S-trans,trans-farnesylthiosalicylic acid (FTS) in inhibiting Ras-transformed cells.
- To determine if FTS specifically interferes with Ras functions.
- To elucidate FTS's effect on Ras membrane localization and degradation.
Main Methods:
- Treatment of H-Ras-transformed (EJ) cells and Rat-1 cells with FTS.
- Analysis of Ras protein levels and membrane localization.
- Measurement of Ras protein half-life.
- Dose-response studies of FTS effects.
Main Results:
- FTS dislodges Ras from cell membranes, facilitating its degradation and reducing total cellular Ras.
- Ras degradation was rapid, with a half-life of 10 hours in FTS-treated cells versus 27 hours in controls.
- FTS demonstrated dose-dependent effects and selectivity towards oncogenic Ras.
- FTS did not affect normal Ras isoforms or other membrane proteins.
Conclusions:
- FTS specifically targets Ras membrane docking, leading to enhanced protein degradation.
- This mechanism underlies FTS's ability to inhibit the growth of Ras-transformed cancer cells.
- FTS represents a potential therapeutic agent for cancers driven by oncogenic Ras.